Table 1.
Demographic and Clinical Characteristics of the Two Group Patients Included in the Study
| mNGS Group | CMT Group | p value | |
|---|---|---|---|
| Male/female (n) | 21/12 | 42/24 | 1 |
| Age (year) | 63.09±15.3 | 63.09±15.2 | 1 |
| APACHE II score | 17.0±4.80 | 17.0±4.80 | 1 |
| PSI score | |||
| Grade III (n) | 7 | 14 | 1 |
| Grade IV (n) | 26 | 52 | 1 |
| CRRT implementation (n) | 6 | 12 | 1 |
| ECMO implementation (n) | 2 | 4 | 1 |
| Organ transplant (n) | 4 | 8 | 1 |
| Immunosuppressor (n) | 14 | 28 | 1 |
| Comorbidities | |||
| Organ transplant (n) | 4 | 8 | 1 |
| COPD (n) | 2 | 4 | 1 |
| Hematologic neoplasms (n) | 2 | 4 | 1 |
| Cerebral hemorrhage | 3 | 6 | 1 |
| Interstitial pneumonia | 1 | 2 | 1 |
| AMI | 2 | 4 | 1 |
| Hyperthyroid crisis | 1 | 2 | 1 |
| ANCA-associated vasculitis | 2 | 4 | 1 |
| Solid tumors | 4 | 8 | 1 |
| Ischemic stroke | 2 | 4 | 1 |
| Traumatic brain injury | 5 | 10 | 1 |
| Lower respiratory tract infection | 3 | 6 | 1 |
| Type of infection (n) | |||
| HAP but not VAP | 3 | 6 | 1 |
| VAP | 30 | 60 | 1 |
| Time from hospitalization to diagnosis of nosocomial pneumonia (days) | 6.6±1.6 | 7.2±2.3 | 0.138 |
| Time from diagnosis of HAP to specimen collection (hours) | 9.1±2.8 | 9.5±3.0 | 0.512 |
| Time of sample submission to results feedback (hours) | 21.8±2.3 | 80.3±5.3 | <0.001 |
Abbreviations: APACHE II, acute physiology and chronic health evaluation II; PSI, Pneumonia Severity Index; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; COPD, chronic obstructive pulmonary disease; AMI, acute myocardial infarction; ANCA, anti-neutrophil cytoplasmic antibody; HAP, hospital-acquired pneumonia; VAP, Ventilator-associated pneumonia.